The New Millennium: time for a change!

The turn of the millennium deserves to be celebrated. That is why we decided some time ago to make January 2000 a special millennium issue. The approach of the new millennium inevitably leads to reminiscence. We therefore decided to indulge both in reflection on the rich history of JCP and in simultaneous speculation on the future. With the help of many people, we have filled this issue with some reflections by our editors on papers from the first issue of JCP in 1947, together with some visionary papers on developments in pathology. We are indebted to all those who have contributed to this issue and extend our thanks to them.

Board membership of JCP
The strength of JCP has always been its multidisciplinary base. To facilitate this ongoing role we are appointing new members of the board to represent those specialties that are currently underrepresented—that is, chemical pathology, haematology, microbiology, immunology, and statistics. In line with this policy, we have also increased the trainee representation of the board to include one person from each discipline. We hope that this will provide new thoughts and ideas, to meet the requirements of trainee pathologists and new consultants as well as those established in their field.

Journal developments
We would also like to take this opportunity to highlight changes in the journal which have occurred during the last two years and to announce some which are imminent. We have reduced the turn around time of submissions to JCP and with the help of our many reviewers, now give authors the initial comment on their paper within an average of five weeks after receipt. Furthermore as a result of the fully electronic in house publishing process, papers are usually published within a three month period after acceptance.

CPD and pathology interactive
In June this year, JCP launched its educational CD-ROM, Pathology Interactive. Financed by the ACP, Pathology Interactive is available as a membership benefit to ACP members and by subscription to non-members. Selected review papers and leaders published in JCP are accompanied by CPD questions generated or moderated by specialty CPD panels. The CPD questions are presented in Pathology Interactive with related literature and as multiple choice questions. There is an automated self testing program, with scoring and analysis of MCQ scores achieved. Completed tests may be saved as portfolio evidence of learning.

In the year 2000, Pathology Interactive will appear quarterly, with 24 papers and further CPD material. The broadening of the Royal College of Pathologists’ view of CPD means that, in the millennium, the range of educational facilities provided by Pathology Interactive will be extended. Instructive case histories, with appropriate questions and model answers, and picture quizzes will provide further access to self learning, while appropriate use of the user notes facility may provide evidence of the reflective process.

Recent discussions with Clair du Boulay, Director of CPD at The Royal College of Pathologists, have resulted in agreement that a range of credits, between 1 and 3, may be awarded for participation in this CPD activity. The actual number of credits to be claimed should be assessed by the individual on the basis of effort expended and learning derived from the activity. This is a self accreditation process, awarded in the following way: one credit should be claimed by participants who read the review article and complete the associated questions; two credits can be claimed if additional reading is done and references followed up; three credits can be claimed if these studies are supplemented by note taking and by identifying learning outcome or further learning needs.

It is felt that this should provide a readily accessible and enjoyable means of CPD activity for all pathologists.

Historical notes
Beginning with this millennium issue, JCP will start to publish short historical notes as page fillers, on a regular basis (see p 26, this issue). We hope that these will provide an interesting short read. The historical fillers have initially been commissioned, but we very much welcome your submissions for this type of brief article.

Open peer review
Peer review has had a crucial role in publishing in medical journals since the 18th century. Since then it has developed somewhat haphazardly, with individual journals producing their own versions, basically dependent on the editor in charge at the time.

During the last 15 years, rational inquiries into the workings of editorial peer review have been undertaken. They began with the publication in 1985 of Stephen Lock’s seminal work on peer review, a book entitled A Difficult Balance, and the decision by JAMA that year to hold a conference to present research, as opposed to opinion, on editorial peer review. Three conferences in this field have now been held and have stimulated research into an area which greatly lacked factual support.

Open review, where the names of the reviewers are known to the authors, first appeared in the journal Cardiovascular Research in 1994. The article fuelled a response from a number of independent critics including Stephen Lock and Richard Smith, past and present editors of the BMJ, and Drummond Rennie of JAMA. These editors all argued that there was no ethical justification for the anonymous system of peer review, as knowledge that their names will be disclosed to authors and the public cannot fail to make reviewers more responsible in their comments. A publication in JAMA in 1998 showed that blinding reviewers to the identity of authors or revealing the identity of reviewers made no editorially significant difference to review quality or review considerations. Certainly in revealing what makes a good publication for a journal, Black et al showed that high quality review ratings were significantly associated with training in epidemiology or...
After much debate at the 1999 editorial board meeting of JCP, we decided that an open review process would be more honest, would give credit to reviewers, and would encourage them to be both polite and constructive in their comments. An argument against it would be the reluctance of junior reviewers to criticise the work of senior researchers for fear of damage to their careers. In short, arguments in favour of an open review process are largely ethical. Several journals, including the BMJ, have opened the review process and we have decided to follow this practice. From now on, reviewers for JCP will be invited to reveal their identity, but we will respect their right to remain anonymous if they so wish. In order to protect our reviewers, however, we will make it clear that the decision to accept a paper or not is an editorial one, so that any authors disagreeing with a decision must address their comments to the editors of the journal. A similar decision to open the peer review process was taken separately by the editorial board of Molecular Pathology.

New copyright procedure
It has long been customary that the authors’ only reward for publishing a paper is exposure and “findability”; there has been no direct payment. Publishers for their part have borne the costs of peer review and of providing the exposure. In return they have taken the rights to their authors’ work and the revenues of publishing, and have made money from allowing third parties to reprint articles or translate and distribute them. Recently some authors have become resentful of the fact that publishers take their rights, don’t always exploit them well, and then insist on requests for permission when authors want to use their own material. Along with other journals in the BMJ Publishing Group, the Journal of Clinical Pathology and its Molecular Pathology edition have traditionally asked authors to assign their copyright to the publisher to exploit those rights, and tackle infringements without having to go back to the author each time. In practice the publisher has, however, always allowed authors to use their material in other publications, and for their own teaching and research purposes without charge. From now on the Journal of Clinical Pathology and Molecular Pathology will change this traditional policy. Authors will no longer be asked to assign their copyright to the publisher. Instead, we will ask for an exclusive licence. In practice this gives the journal almost the same control as before, but authors will no longer have to ask for permission to use their material for any non-commercial use. In addition, we will give one nominated author, research group, or institution 10% of the revenue we make from a commercial reprint order (over £1000) for their paper. We hope that you will appreciate the changes to the JCP and that you will enjoy this special issue. We wish you all the best for the new millennium.

HELEN HOLZEL
PAUL J VAN DIEST

30 Kennard CJ. Giving something back to the authors. J Neurol Neurosurg Psychiatry 1999;67:419–27.

Millennium Festival of Medicine
This special issue of JCP is a part of the Millennium Festival of Medicine—a programme of diverse events and activities for healthcare professionals and the wider public running throughout the year in the United Kingdom to celebrate the turn of the century and mark the advances and challenges in medicine. At the heart of the celebrations is the Festival Keynote Conference (6–10 November 2000, London). Parallel sessions which may be of interest to readers of JCP are: Testing and treating healthy people (6 November) Molecular biology and medicine (8 November) Emerging infections, diseases and international health problems (10 November).

Further information on the programme of events and activities is available at www.medicine2000.org or by contacting tel +44 (0)171 383 6872; fax +44 (0)171 383 6220; email: medicine2000@medicine2000.org.
Reflections on the first issue of JCP

Microbiology

Leading the way as the first article in the first issue of JCP in 1947, Bedson wrote a magnificent review of the laboratory diagnosis of virus infections of man. He showed a formidable understanding of the then current situation, stating that it was still impossible to say whether viruses were living microorganisms or not. He highlighted the doubt that all the agents grouped together as viruses were “of the same nature.” How right he was. The major group of agents he discussed were the so called large viruses. His descriptions of the clinical picture and means of investigating the “viral causes” of trachoma inclusion conjunctivitis, lymphogranuloma venereum, and psittacosis were so well observed that they remain true today.

Bedson discussed the different means of viral diagnosis available in 1947. He described the use of specific histological change, virus isolation by use of eggs or animal inoculation, for example the use of monkeys as the only available means of detecting poliovirus. Serological investigations included use of precipitins, agglutination, complement fixation, and the new haemagglutination inhibition test for influenza. He discussed how complement fixation could be used for the detection of variola antigen in the vesicles and crusts of skin lesions and the novel use of red cell agglutination for virus detection. In his final remarks, Bedson emphasised the important part which the laboratory can play “not just occasionally by making special investigations but in an everyday routine way.”

Taking the role of microscopy further, Madeley in the Origins series in 1997 described the history of electron microscopy (EM) from its origin in Germany in 1934 to its development as a valuable diagnostic tool. The first pictures of viruses, those of plant viruses such as tobacco mosaic virus, were published in 1941. During the following 10 years micrographs of one virus after another appeared. By the 1960s, the use of the electron microscope had progressed to become an integral part of the diagnosis of smallpox. It was purchased for this reason by a considerable number of diagnostic laboratories. With the elimination of the disease in 1976, however, a new role evolved and EM became used for the diagnosis of viral skin lesions such as warts and molluscum contagiosum. Its importance as a diagnostic tool had receded. By the mid 1970s viruses had been identified as the cause of many diseases. In particular, they were thought to be the major cause of common episodes of diarrhoea and vomiting. Madeley described the progress of the recognition of EM as a tool for the diagnosing of viral causes of diarrhoea common in children, both here and in the tropics. By way of Kapikian’s use of EM in finding Norwalk agent as the cause of an outbreak of diarrhoea in Ohio in 1972, Madeley led us through Bishop’s findings of rotavirus in thin section EM of biopsies from children with possible malabsorption, to the work of Flewett. In 1973, Flewett showed that rotavirus could be seen by EM directly in stool extracts. In his own work in 1975, Madeley used EM to demonstrate the importance of mosquito-borne viruses such as malaria and yellow fever. In the 1980s Caul and Appleton used EM to highlight the importance of a variety of small round structured viruses.

Madeley wrote of the gradual fall in the use of this expensive piece of equipment in the current climate of cost conscious diagnostic laboratories. He ended by saying that use of EM with a speed of diagnosis some 15 minutes at its best, coupled with its versatility in being able to detect a wide variety of viruses without prior selection, should ensure its continued use.

A diagnosis of viral infection made, but then what? In his article in 1999 on recent advances in antiviral therapy, Kinchington discusses the range of antiviral treatment now available. Drugs for treating HIV infection are discussed and the explanation of their activity at molecular level makes a complex subject interesting for experts and non-experts alike. The arrival of HIV had changed the perception of the importance of the specialist department of virology. It led to an increased activity in antiviral research into novel treatments for other viruses, including hepatitis B and C and the growing herpes virus group. Kinchington expressed the view that future antiviral chemotherapy will be concerned with the search for compounds that can target viral enzymes. He wrote that the identification and cloning of viral genomes is now routine, because of the availability of PCR technology, even when
Department of Microbiology, Hospital for Sick Children, Great Ormond Street, London WC1, UK


Haematology

What happened in the world of haematology in the latter half of the last millennium and how has this been reflected in the pages of JCP? A sample, chosen by me, of a few papers published early, somewhat later, and much more recently in the Journal's publishing history will certainly illustrate my enthusiasm, even if they will not answer either question satisfactorily for many haematologists.

In the very early days, Dacie and White1 published a review (in those days reviews were often both scholarly and truly elegantly written affairs, and this is such an example) of erythropoiesis and its study by bone marrow biopsy. I know microscope lenses and condensers have improved enormously since then, as has modern colour photography, but the careful observation and descriptive power of conscientious microscopists still shines through. Observation of snapshots of this dynamic organ was really all that was available because bone marrow culture systems, as we know them today, would have been science fiction to haematologists in the 1940s. It is also fascinating to see the sang froid with which haematologists in those days would contemplate and perform a trephine biopsy on the sternum!

Massive leaps in the technology of cell counting, understanding of clotting, and other areas took place between 1949 and the 1970s. However, although I remain at heart a morphologist, it is the more “basic biology” advances (especially as they affect malignant haematology) that have really gripped my imagination. In 1975 Habeshaw and Stuart2 reported on cell receptor studies in histiocytic lymphoma, still called reticulum cell sarcoma in those days. Their paper illustrated the way early techniques of sheep red cell rosetting and fluorescence microscopy with polyclonal antibodies could be used to determine T, B, or null phenotypes from single cell suspensions of these lymphomas. Of course such techniques had already been used for a few years by pure immunologists and early classifications, of childhood leukaemia in particular, were already being compiled. The dawn of the true expansion of immunological diagnosis is reflected, six years later, in the review by Hoffbrand and Janossy.3 Not only had the common acute lymphoblastic leukaemia antigen been discovered by Greaves, but Ritz had produced a monoclonal antibody to it, one among an expanding battery of monoclonal antibodies to T, B, and myeloid cells to come out of numerous laboratories round the world. The speed with which such reagents entered routine diagnosis was extraordinary. The size of antibody panels soon demanded flow cytometry, both for the improved accuracy that came from analysing large numbers of fluorescing cells and in order that fluorescence microscopists were not submerged by the deluge.

The last 10 years have witnessed a similarly breathtaking explosion in what was once called “the new genetics.” DiGiuseppe and Kastan4 provided, in 1997, a review of apoptosis in haematological malignancies which explored current knowledge of the action of a number of genes such as bcl-2, p53, Fas, and perhaps the most extensively and longest studied genetic rearrangement, the fusion gene BCR/ABL—and of the effects they might have on programmed cell death and resistance to chemotherapy. Molecular biological knowledge is now expanding faster than haematologists can assimilate it; we can barely begin to frame the important questions about how best to exploit this knowledge, let alone answer those questions. My feeling is that over the next 20 years we shall discover just how difficult it really is to harness these discoveries and decide which are truly important to our every day management of haematological malignancy. In the meantime it’s a field day for the basic scientists!

M M REID

Department of Haematology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, UK


On “Familial intestinal polyposis” by C E Dukes

All papers from the first issue are well before my time, but I had no problem making my choice. Going through the index, my eye was immediately caught by a name (Dukes), and seeing the title of the paper (Familial intestinal polyposis) I realised this had to be my pick. With today’s knowledge, it was fun to look back and see what at that time was already known and what may have been wrong or incomplete.

Well, nothing much was wrong. The paper gives an accurate description of the first data on families with polyposis and colorectal cancer. It is explained that in some families multiple polyps occur, strictly confined to the colon, and that this predisposes to colon cancer. Several statements still hold true: the young age at diagnosis of cancer, the “tendency for malignant disease to begin at an earlier age period in each succeeding generation,” the need for “constant medical supervision,” and that “no other method of treatment than surgery has any permanent effect on the course of the disease.” However, the mentioned “waiting game,” where “a radical excision may have considerable influence on the course of the disease” was not only had the common acute lymphoblastic leukaemia antigen been discovered by Greaves, but Ritz had produced a monoclonal antibody to it, one among an expanding battery of monoclonal antibodies to T, B, and myeloid cells to come out of numerous laboratories round the world. The speed with which such reagents entered routine diagnosis was extraordinary. The size of antibody panels soon demanded flow cytometry, both for the improved accuracy that came from analysing large numbers of fluorescing cells and in order that fluorescence microscopists were not submerged by the deluge.

The last 10 years have witnessed a similarly breathtaking explosion in what was once called “the new genetics.” DiGiuseppe and Kastan provided, in 1997, a review of apoptosis in haematological malignancies which explored current knowledge of the action of a number of genes such as bcl-2, p53, Fas, and perhaps the most extensively and longest studied genetic rearrangement, the fusion gene BCR/ABL—and of the effects they might have on programmed cell death and resistance to chemotherapy. Molecular biological knowledge is now expanding faster than haematologists can assimilate it; we can barely begin to frame the important questions about how best to exploit this knowledge, let alone answer those questions. My feeling is that over the next 20 years we shall discover just how difficult it really is to harness these discoveries and decide which are truly important to our every day management of haematological malignancy. In the meantime it’s a field day for the basic scientists!

M M REID

Department of Haematology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, UK


On “Familial intestinal polyposis” by C E Dukes

All papers from the first issue are well before my time, but I had no problem making my choice. Going through the index, my eye was immediately caught by a name (Dukes), and seeing the title of the paper (Familial intestinal polyposis) I realised this had to be my pick. With today’s knowledge, it was fun to look back and see what at that time was already known and what may have been wrong or incomplete.

Well, nothing much was wrong. The paper gives an accurate description of the first data on families with polyposis and colorectal cancer. It is explained that in some families multiple polyps occur, strictly confined to the colon, and that this predisposes to colon cancer. Several statements still hold true: the young age at diagnosis of cancer, the “tendency for malignant disease to begin at an earlier age period in each succeeding generation,” the need for “constant medical supervision,” and that “no other method of treatment than surgery has any permanent effect on the course of the disease.” However, the mentioned “waiting game,” where “a radical excision may have considerable influence on the course of the disease” was not only had the common acute lymphoblastic leukaemia antigen been discovered by Greaves, but Ritz had produced a monoclonal antibody to it, one among an expanding battery of monoclonal antibodies to T, B, and myeloid cells to come out of numerous laboratories round the world. The speed with which such reagents entered routine diagnosis was extraordinary. The size of antibody panels soon demanded flow cytometry, both for the improved accuracy that came from analysing large numbers of fluorescing cells and in order that fluorescence microscopists were not submerged by the deluge.
probably be explained by the chance mating of two carriers, leading to an excessive number of affected individuals in this family.

Although all the patients described in the paper are considered to have the same syndrome, knowledge has progressed and we now discern several syndromes. From the description of the patients’ histories, it seems that most of them had a disease which we would now designate familial adenomatous polyposis (FAP). However, the four very young patients would now be considered to have juvenile polyposis, and the patients from the original Warthin paper which was cited by Dukes (cancer family “G”) were later, of course, found to have a different disease which we now call hereditary non-polyposis colorectal cancer (HNPCC) syndrome, based on a germline mutation in one of the genes coding for the DNA mismatch repair apparatus.

It is stated that “members of polyposis families show no special proclivity to the development of tumours in any other organ of the body than the intestine,” which we now know not to be true. Several phenotypical variants of this inherited disease caused by a germline mutation in the APC gene exist. Gardner’s syndrome (polyposis, epidermoid cysts, and osteomas), a proportion of the cases with Turcot’s syndrome (polyposis and brain tumours), and AFAP (attenuated familial adenomatous polyposis—that is, APC mutations with less than 100 polyps and colorectal cancer at a later age than in “common” FAP) all belong within the spectrum of FAP. In addition, since many FAP patients do not now die from colorectal cancer, other tumours appear, such as duodenal polyps, desmoid tumours, and thyroid and hepatocellular cancers. HNPCC also involves an inherited predisposition to cancer which is certainly not limited to the large intestine. Endometrial, ovarian, gastric, and urothelial cancers often occur in patients with HNPCC, as well as cancers at other sites. The combination of sebaceous gland tumours and an internal malignancy is known as Muir-Torre syndrome. Based on the presence of microsatellite instability, it has been suggested that a proportion of Muir-Torre syndrome cases would be variants of HNPCC.

Nevertheless, there is no doubt that this review from over 50 years ago is in retrospect a seminal paper, which has to be reviewed. The natural history and underlying complications could be reviewed. The natural history in non-fatal cases seemed to have been that patients would eventually undergo spontaneous recovery after a period of months or years. This suggests that steroids probably do not radically alter the time course of the disease, although they undoubtedly relieve the acute symptoms. Indeed the only treatment identified by Harrison is the curiously therapeutic effect of temporal artery biopsy in relieving symptoms (in 21 cases).

The current treatment of steroids with or without second line immunosuppressive agents, although not available in 1948, was introduced in the 1950s, and again we have seen little in the way of changes to the therapeutic approach. Indeed this is a criticism of the approach to many immunological diseases, where we are still reliant on 40 year old treatments, an indicator perhaps of the discrepancy between the huge strides made in basic immunology compared with the rather limited progress in translating this knowledge into clinically useful advances in treatment.

G P SPICKETT

Regional Department of Immunology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Is there really anything new under the sun? I wondered, as I was asked to select a chemical pathology paper from the first volume of the first edition of JCP, to discuss in the millennium issue of the journal. Furthermore, would it be possible for me to find a paper from over 50 years ago that would reflect chemical pathology practice at the time and contrast this with current trends in the field as we lead up to the millennium celebrations? A paper that did stand out was that by E J King and R J Garner, from the British Postgraduate Medical School, entitled “The colorimetric determination of glucose.” This was starkly different from those current papers that one tends to browse through, describing knock out mice, prions, cytokines, retroviruses, genetically modified foodstuffs, or adhesion molecules. It was written in 1947 during the preconception years of the NHS, at a time when laboratory accreditation, the Royal College of Pathology, CME log books, and NEQAS were only twinkle in laboratory medicine’s eyes.

The first striking feature of this paper is the mention in the introduction of the difficulty the authors had in obtaining analytic reagent grade quality reagents for the glucose colorimetric assay; they attributed this to the war years. Alas, in this sense perhaps little has changed, for as I write this article British forces attack Serbian positions in the Balkans, a tragic example of a “...small war on the heels of small war.” The contamination of their sodium carbonate reagent with sodium bicarbonate resulted in poor colour stability and variable glucose assay results. Today we perhaps take for granted the ease of obtaining high quality reagents off the shelf from large commercial suppliers.

Another feature of this paper is the politically incorrect use of non-SI units. This is almost guaranteed to cause enthusiasts from the pro-SI and anti-SI lobbies to write letters to the Journal to generate debate, although I have to say that mmol/1 is a lot easier to write than mg per 100 ml for the units of glucose. Nevertheless, there is still no international agreement on units for reporting clinical chemistry results.

As anyone should know who works in a modern chemical pathology laboratory, fast turnaround times are important for clinicians to ensure optimal patient management. However, I cannot imagine that manually filtering blood, after protein precipitation, followed by 10 minutes of boiling the filtrate with copper reagent, followed by another 10 minutes for assay colour development with Folin-Wu phosphomolybdic acid would inspire an overstretched MLSO to assay many blood samples for glucose. Nor would the beer barrel quantities of sample and reagent attract delight in a multidiscipline combined laboratory working flat out in a shift system; amazingly, the final assay reaction volume exceeded 5 ml! I would be surprised, also, if the authors of this historic paper would have guessed that 50 years later glucose could be measured within minutes, using microvolumes of sample and reagent by dry chemistry techniques, biosensors, or multianalysers, some of which can also measure at least 20 other analytes.

Furthermore, would they have prophesied that diabetic patients would be monitoring their own blood glucose as part of near patient testing and using these results to adjust their insulin? In addition, could they have believed that in 1995 more than £40 million would be spent in the United Kingdom on home glucose monitoring alone?

Having read this fascinating, seminal, and historic paper by King and Garner I can only conclude that we have come a long way in laboratory medicine since they published their article. With the exponential growth in scientific and medical knowledge we are likely to have many further surprises in the new millennium. Fifty years is a long time in laboratory medicine and we need to be prepared for the changes if we are to survive under the sun.

M A CROOK
Department of Chemical Pathology, Guy’s and St Thomas’ Hospital, London SE1, UK